Composition and Method for Treating Neurological Disease (2018)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 15/898,143, filed Feb 15, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,213,393 | Composition and Method for Treating Neurological Disease In force · High confidence UsedRemaining | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,500,170 | Composition and Method for Treating Neurological Disease In force · High confidence | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,512,617 | Composition and Method for Treating Neurological Disease In force · High confidence | Adamas Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,833,121 | Composition and Method for Treating Neurological Disease In force · Medium confidence | Adamas Pharmaceuticals, Inc. | In force | Medium confidence | ||
| Application 16/268,373 | Composition and Method for Treating Neurological Disease Abandoned Abandoned Mar 1, 2021 | Adamas Pharmaceuticals, Inc. | Abandoned | Abandoned Mar 1, 2021 | ||
| Application 16/670,732 | Composition and Method for Treating Neurological Disease Abandoned Abandoned Apr 9, 2021 | Adamas Pharmaceuticals, Inc. | Abandoned | Abandoned Apr 9, 2021 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Adamas Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.